Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11095608 | 1.00 | EPHX2 (0.45) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL29186322 | 1.00 | EPHX2 (0.45) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL5696819 | 1.00 | EPHX2 (0.45) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL11092421 | 1.00 | EPHX2 (0.45) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL10633025 | 1.00 | EPHX2 (0.45) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL4006880 | 0.98 | EPHX2 (0.42) | EPHX2DNM1KDM5AKDM4CPHF8 | |
| SCHEMBL995722 | 0.94 | LMNA (0.40) | EPHX2DNM1ALDH1A1 | |
| SCHEMBL9357923 | 0.92 | ALDH1A1 (0.41) | EPHX2DNM1KDM5AKDM4CALDH1A1 | |
| SCHEMBL5547671 | 0.85 | LMNA (0.36) | EPHX2DNM1ALDH1A1 | |
| SCHEMBL8149451 | 0.85 | LMNA (0.36) | EPHX2DNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8222200-B2 | Organic compounds | GIVAUDAN SA (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222200-B2 | Organic compounds | GIVAUDAN SA (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| EP-1325051-B1 | USE AS CATALYST FOR FORMING URETHANES, OF FLUORINATED AND TRIVALENT METAL ACID SALTS, COMPOSITION CONTAINING SAME AND METHODS USING SAME | RHODIA CHIMIE SA (FR) | 2008-08-20 | — | — | EP | disclosed |
| EP-1326711-B1 | USE OF TIN DERIVATIVES AS CATALYSTS FOR TRANSFORMING CARBAMATES, CARBAMATE COMPOSITIONS COMPRISING SAID CATALYST AND METHOD FOR TRANSFORMING CARBAMATES | RHODIA CHIMIE SA (FR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1326711-A1 | USE OF TIN DERIVATIVES AS CATALYSTS FOR TRANSFORMING CARBAMATES, CARBAMATE COMPOSITIONS COMPRISING SAID CATALYST AND METHOD FOR TRANSFORMING CARBAMATES | RHODIA CHIMIE (FR) | 2003-07-16 | — | — | EP | disclosed |
| EP-1325051-A1 | USE AS CATALYST FOR FORMING URETHANES, OF FLUORINATED AND TRIVALENT METAL ACID SALTS, COMPOSITION CONTAINING SAME AND METHODS USING SAME | RHODIA CHIMIE (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002031014-A1 | USE AS CATALYST FOR FORMING URETHANES, OF FLUORINATED AND TRIVALENT METAL ACID SALTS, COMPOSITION CONTAINING SAME AND METHODS USING SAME | RHODIA CHIMIE (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030565-A1 | USE OF TIN DERIVATIVES AS CATALYSTS FOR TRANSFORMING CARBAMATES, CARBAMATE COMPOSITIONS COMPRISING SAID CATALYST AND METHOD FOR TRANSFORMING CARBAMATES | RHODIA CHIMIE (FR) | 2002-04-18 | — | — | WO | disclosed |
| EP-0143320-B1 | METHOD FOR THE PREPARATION OF ISOCYANATES BY THERMAL DECOMPOSITION OF URETHANES | BASF Aktiengesellschaft (DE) | 1988-01-20 | — | — | EP | disclosed |
| EP-0078005-B1 | METHOD FOR THE PREPARATION OF ISOCYANATES BY PYROLYSIS OF URETHANES | BASF Aktiengesellschaft (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0143320-A2 | Method for the preparation of isocyanates by thermal decomposition of urethanes | BASF Aktiengesellschaft (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0078005-A1 | Method for the preparation of isocyanates by pyrolysis of urethanes | BASF Aktiengesellschaft (DE) | 1983-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | EPHX2 4729/4885DNM1 4230/4885KDM5A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.